Role of probiotics on nonalcoholic fatty liver disease related cells

WANG Bin; CAI Min; HUANG Ling; JIANG Ziting; TONG Minsi; LI Li

doi:10.3969/j.issn.1006-0111.2018.05.006

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 36 Issue 5

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2018 > 36(5): 409-416

WANG Bin, CAI Min, HUANG Ling, JIANG Ziting, TONG Minsi, LI Li. Role of probiotics on nonalcoholic fatty liver disease related cells[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 409-416. doi: 10.3969/j.issn.1006-0111.2018.05.006

Citation:

WANG Bin, CAI Min, HUANG Ling, JIANG Ziting, TONG Minsi, LI Li. Role of probiotics on nonalcoholic fatty liver disease related cells[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 409-416. doi: 10.3969/j.issn.1006-0111.2018.05.006

Role of probiotics on nonalcoholic fatty liver disease related cells

doi: 10.3969/j.issn.1006-0111.2018.05.006

Department of Gastroenterology, Yangpu Hospital Affiliated to Tongji University, Shanghai 200090, China

Received Date: 2018-01-21
Rev Recd Date: 2018-07-11

Abstract

Objective To explore the effects and mechanisms of probiotics on nonalcoholic fatty liver disease related intestinal epithelial cells, Kupffer cells and liver parenchymal cells. Methods Human intestinal epithelial cells Caco-2, rat Kupffer cells and mouse liver parenchymal cell AML12 were divided into eight groups respectively:the control group, LPS group, Lactobacillus acidophilus group, LPS+Lactobacillus acidophilus group, Enterococcus faecalis group, LPS+Enterococcus faecalis group, Bifidobacterium group and LPS+Bifidobacterium group. All cells were incubated for 6 h and collected to detect the expression of tight junction related factors and cell permeability of human intestinal epithelial cells Caco-2, the levels of functional factors, IκB and p-IκB of rat Kupffer cells, the expression of lipid metabolism genes and lipid absorption of hepatocytes AML12. Results Probiotics significantly inhibited the expression of Occludin, Claudin-1, JAM, ZO-1 and cell permeability induced by LPS in human intestinal epithelial cells Caco-2. Probiotics decreased the levels of TNF-α, IFN-γ, IL-6 and increased the levels of IL-4, IL-10, IL-13 caused by LPS in rat Kupffer cells. The protein level of p-IκB was also inhibited by probiotics. In addition, probiotics significantly inhibited the upregulation of ACACA, SREBF1, FAS, FABP3, FABP4, DGAT1 and lipid absorption induced by LPS in mouse liver parenchymal cells AML12. Conclusion Probiotics can protect nonalcoholic fatty liver disease through promoting the expression of intestinal epithelial tight junction related factors, reducing epithelial cells permeability, inhibiting the activity of NF-κB pathway to decrease the expression of proinflammatory cytokines and increase the levels of anti-inflammatory cytokines in Kuffer cells, inhibiting lipid metabolism genes expression and lipid absorption of hepatocytes.
- nonalcoholic fatty liver disease,
- probiotics,
- Caco-2,
- cell permeability,
- Kupffer cell,
- p-IκB,
- AML12,
- lipid absorption

References

[1]	中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版)[J]. 中华肝脏病杂志, 2010, 19(3):163-166.
[2]	KE P, SHAO BZ, XU ZQ, et al. Intestinal autophagy and its pharmacological control in inflammatory bowel disease[J]. Front Immunol, 2016, 7:695.
[3]	XIN D, ZONG-SHUN L, BANG-MAO W, et al. Expression of intestinal tight junction proteins in patients with non-alcoholic fatty liver disease[J]. Hepatogastroenterology, 2014, 61(129):136-140.
[4]	BASHIARDES S, SHAPIRO H, ROZIN S, et al. Non-alcoholic fatty liver and the gut microbiota[J]. Mol Metab, 2016, 5(9):782-794.
[5]	BAO Y. The progress of studying the mechanisms of immune cells in the regulation of non-alcoholic fatty liver diseases[J]. Zhonghua Gan Zang Bing Za Zhi, 2017, 25(7):553-556.
[6]	CHEN J, LI J, YIU JHC, et al. TRIF-dependent Toll-like receptor signaling suppresses Scd1 transcription in hepatocytes and prevents diet-induced hepatic steatosis[J]. Sci Signal, 2017, 10(491):eaal3336.
[7]	MOUZAKI M, BANDSMA R. Targeting the gut microbiota for the treatment of non-alcoholic fatty liver disease[J]. Curr Drug Targets, 2015, 16(12):1324-1331.
[8]	KELISHADI R, FARAJIAN S, MIRLOHI M. Probiotics as a novel treatment for non-alcoholic fatty liver disease; a systematic review on the current evidences[J]. Hepat Mon, 2013, 13(4):e7233.
[9]	LYU M, WANG YF, FAN GW, et al. Balancing herbal medicine and functional food for prevention and treatment of cardiometabolic diseases through modulating gut microbiota[J]. Front Microbiol, 2017, 8:2146.
[10]	LI M, WANG B, SUN X, et al. Upregulation of intestinal barrier function in mice with DSS-induced colitis by a defined bacterial consortium is associated with expansion of IL-17A producing gamma delta T cells[J]. Front Immunol, 2017, 8:824.
[11]	BETRAPALLY NS, GILLEVET PM, BAJAJ JS. Gut microbiome and liver disease[J]. Transl Res, 2017, 179:49-59.
[12]	MU C, YANG Y, ZHU W. Gut microbiota:the brain peacekeeper[J]. Front Microbiol, 2016, 7:345.
[13]	BUDDEN KF, GELLATLY SL, WOOD DL, et al. Emerging pathogenic links between microbiota and the gut-lung axis[J]. Nat Rev Microbiol, 2017, 15(1):55-63.
[14]	ZHU W, GREGORY JC, ORG E, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk[J]. Cell, 2016, 165(1):111-124.
[15]	SHEN ZH, ZHU CX, QUAN YS, et al. Relationship between intestinal microbiota and ulcerative colitis:mechanisms and clinical application of probiotics and fecal microbiota transplantation[J]. World J Gastroenterol, 2018, 24(1):5-14.
[16]	CAVALCANTI NETO MP, AQUINO JS, ROMAO DA SILVA LF, et al. Gut microbiota and probiotics intervention:a potential therapeutic target for management of cardiometabolic disorders and chronic kidney disease?[J]. Pharmacol Res, 2018, 130:152-163.
[17]	WAN MLY, EL-NEZAMI H. Targeting gut microbiota in hepatocellular carcinoma:probiotics as a novel therapy[J]. Hepatobiliary Surg Nutr, 2018, 7(1):11-20.
[18]	钱晓婷,章期生. 双歧杆菌三联活菌胶囊对非酒精性脂肪性肝炎患者血清内毒素和炎症因子的影响[J]. 中国微生态学杂志, 2014, 26(4):435-437.
[19]	WANG W, SHI LP, SHI L, et al. Efficacy of probiotics on the treatment of non-alcoholic fatty liver disease[J]. Zhonghua Nei Ke Za Zhi, 2018, 57(2):101-106.
[20]	MANZHALⅡ E, VIRCHENKO O, FALALYEYEVA T, et al. Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis:a pilot trial[J]. J Dig Dis, 2017, 18(12):698-703.
[21]	DAI X, WANG B. Role of gut barrier function in the pathogenesis of nonalcoholic fatty liver disease[J]. Gastroenterol Res Pract, 2015, 2015:287348.
[22]	ZHU L, BAKER RD, BAKER SS. Gut microbiome and nonalcoholic fatty liver diseases[J]. Pediatr Res, 2015, 77(1-2):245-251.
[23]	杨群菲,吴建业. 双歧杆菌四联活菌片保护非酒精性脂肪性肝炎患者肠黏膜屏障功能的机制及疗效[J]. 中国微生态学杂志, 2015, 27(6):696-698.
[24]	RITZE Y, BARDOS G, CLAUS A, et al. Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice[J]. PLoS One, 2014, 9(1):e80169.
[25]	MIYAKE Y, YAMAMOTO K. Role of gut microbiota in liver diseases[J]. Hepatol Res, 2013, 43(2):139-146.
[26]	SOHN W, JUN DW, LEE KN, et al. Lactobacillus paracasei induces M2-dominant kupffer cell polarization in a mouse model of nonalcoholic steatohepatitis[J]. Dig Dis Sci, 2015, 60(11):3340-3350.
[27]	ANEST V, HANSON JL, COGSWELL PC, et al. A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression[J]. Nature, 2003, 423(6940):659-663.
[28]	KIM YA, KEOGH JB, CLIFTON PM. Probiotics, prebiotics, synbiotics and insulin sensitivity[J]. Nutr Res Rev, 2018,31(1):35-51.
[29]	SHEN F, ZHENG RD, SUN XQ, et al. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease[J]. HBPD Int, 2017, 16(4):375-381.
[30]	IBRAHIM SH, HIRSOVA P, GORES GJ. Non-alcoholic steatohepatitis pathogenesis:sublethal hepatocyte injury as a driver of liver inflammation[J]. Gut, 2018, 67(5):963-972.
[31]	郑啼婴,李瑜元,聂玉强,等. 肠道菌群对非酒精性脂肪性肝病病变程度的影响[J]. 广州医科大学学报,2016, 1:9-13.
[32]	MALAGUARNERA M, VACANTE M, ANTIC T, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis[J]. Dig Dis Sci, 2012, 57(2):545-553.
[33]	NABAVI S, RAFRAF M, SOMI MH, et al. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease[J]. J Dairy Sci, 2014, 97(12):7386-7393.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(2667) PDF downloads(389) Cited by()

Proportional views

Role of probiotics on nonalcoholic fatty liver disease related cells

Department of Gastroenterology, Yangpu Hospital Affiliated to Tongji University, Shanghai 200090, China

Received Date: 2018-01-21

Rev Recd Date: 2018-07-11

Key words:

Abstract: Objective To explore the effects and mechanisms of probiotics on nonalcoholic fatty liver disease related intestinal epithelial cells, Kupffer cells and liver parenchymal cells. Methods Human intestinal epithelial cells Caco-2, rat Kupffer cells and mouse liver parenchymal cell AML12 were divided into eight groups respectively:the control group, LPS group, Lactobacillus acidophilus group, LPS+Lactobacillus acidophilus group, Enterococcus faecalis group, LPS+Enterococcus faecalis group, Bifidobacterium group and LPS+Bifidobacterium group. All cells were incubated for 6 h and collected to detect the expression of tight junction related factors and cell permeability of human intestinal epithelial cells Caco-2, the levels of functional factors, IκB and p-IκB of rat Kupffer cells, the expression of lipid metabolism genes and lipid absorption of hepatocytes AML12. Results Probiotics significantly inhibited the expression of Occludin, Claudin-1, JAM, ZO-1 and cell permeability induced by LPS in human intestinal epithelial cells Caco-2. Probiotics decreased the levels of TNF-α, IFN-γ, IL-6 and increased the levels of IL-4, IL-10, IL-13 caused by LPS in rat Kupffer cells. The protein level of p-IκB was also inhibited by probiotics. In addition, probiotics significantly inhibited the upregulation of ACACA, SREBF1, FAS, FABP3, FABP4, DGAT1 and lipid absorption induced by LPS in mouse liver parenchymal cells AML12. Conclusion Probiotics can protect nonalcoholic fatty liver disease through promoting the expression of intestinal epithelial tight junction related factors, reducing epithelial cells permeability, inhibiting the activity of NF-κB pathway to decrease the expression of proinflammatory cytokines and increase the levels of anti-inflammatory cytokines in Kuffer cells, inhibiting lipid metabolism genes expression and lipid absorption of hepatocytes.

HTML

Reference (33)

[1]	中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版)[J]. 中华肝脏病杂志, 2010, 19(3):163-166.
[2]	KE P, SHAO BZ, XU ZQ, et al. Intestinal autophagy and its pharmacological control in inflammatory bowel disease[J]. Front Immunol, 2016, 7:695.
[3]	XIN D, ZONG-SHUN L, BANG-MAO W, et al. Expression of intestinal tight junction proteins in patients with non-alcoholic fatty liver disease[J]. Hepatogastroenterology, 2014, 61(129):136-140.
[4]	BASHIARDES S, SHAPIRO H, ROZIN S, et al. Non-alcoholic fatty liver and the gut microbiota[J]. Mol Metab, 2016, 5(9):782-794.
[5]	BAO Y. The progress of studying the mechanisms of immune cells in the regulation of non-alcoholic fatty liver diseases[J]. Zhonghua Gan Zang Bing Za Zhi, 2017, 25(7):553-556.
[6]	CHEN J, LI J, YIU JHC, et al. TRIF-dependent Toll-like receptor signaling suppresses Scd1 transcription in hepatocytes and prevents diet-induced hepatic steatosis[J]. Sci Signal, 2017, 10(491):eaal3336.
[7]	MOUZAKI M, BANDSMA R. Targeting the gut microbiota for the treatment of non-alcoholic fatty liver disease[J]. Curr Drug Targets, 2015, 16(12):1324-1331.
[8]	KELISHADI R, FARAJIAN S, MIRLOHI M. Probiotics as a novel treatment for non-alcoholic fatty liver disease; a systematic review on the current evidences[J]. Hepat Mon, 2013, 13(4):e7233.
[9]	LYU M, WANG YF, FAN GW, et al. Balancing herbal medicine and functional food for prevention and treatment of cardiometabolic diseases through modulating gut microbiota[J]. Front Microbiol, 2017, 8:2146.
[10]	LI M, WANG B, SUN X, et al. Upregulation of intestinal barrier function in mice with DSS-induced colitis by a defined bacterial consortium is associated with expansion of IL-17A producing gamma delta T cells[J]. Front Immunol, 2017, 8:824.
[11]	BETRAPALLY NS, GILLEVET PM, BAJAJ JS. Gut microbiome and liver disease[J]. Transl Res, 2017, 179:49-59.
[12]	MU C, YANG Y, ZHU W. Gut microbiota:the brain peacekeeper[J]. Front Microbiol, 2016, 7:345.
[13]	BUDDEN KF, GELLATLY SL, WOOD DL, et al. Emerging pathogenic links between microbiota and the gut-lung axis[J]. Nat Rev Microbiol, 2017, 15(1):55-63.
[14]	ZHU W, GREGORY JC, ORG E, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk[J]. Cell, 2016, 165(1):111-124.
[15]	SHEN ZH, ZHU CX, QUAN YS, et al. Relationship between intestinal microbiota and ulcerative colitis:mechanisms and clinical application of probiotics and fecal microbiota transplantation[J]. World J Gastroenterol, 2018, 24(1):5-14.
[16]	CAVALCANTI NETO MP, AQUINO JS, ROMAO DA SILVA LF, et al. Gut microbiota and probiotics intervention:a potential therapeutic target for management of cardiometabolic disorders and chronic kidney disease?[J]. Pharmacol Res, 2018, 130:152-163.
[17]	WAN MLY, EL-NEZAMI H. Targeting gut microbiota in hepatocellular carcinoma:probiotics as a novel therapy[J]. Hepatobiliary Surg Nutr, 2018, 7(1):11-20.
[18]	钱晓婷,章期生. 双歧杆菌三联活菌胶囊对非酒精性脂肪性肝炎患者血清内毒素和炎症因子的影响[J]. 中国微生态学杂志, 2014, 26(4):435-437.
[19]	WANG W, SHI LP, SHI L, et al. Efficacy of probiotics on the treatment of non-alcoholic fatty liver disease[J]. Zhonghua Nei Ke Za Zhi, 2018, 57(2):101-106.
[20]	MANZHALⅡ E, VIRCHENKO O, FALALYEYEVA T, et al. Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis:a pilot trial[J]. J Dig Dis, 2017, 18(12):698-703.
[21]	DAI X, WANG B. Role of gut barrier function in the pathogenesis of nonalcoholic fatty liver disease[J]. Gastroenterol Res Pract, 2015, 2015:287348.
[22]	ZHU L, BAKER RD, BAKER SS. Gut microbiome and nonalcoholic fatty liver diseases[J]. Pediatr Res, 2015, 77(1-2):245-251.
[23]	杨群菲,吴建业. 双歧杆菌四联活菌片保护非酒精性脂肪性肝炎患者肠黏膜屏障功能的机制及疗效[J]. 中国微生态学杂志, 2015, 27(6):696-698.
[24]	RITZE Y, BARDOS G, CLAUS A, et al. Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice[J]. PLoS One, 2014, 9(1):e80169.
[25]	MIYAKE Y, YAMAMOTO K. Role of gut microbiota in liver diseases[J]. Hepatol Res, 2013, 43(2):139-146.
[26]	SOHN W, JUN DW, LEE KN, et al. Lactobacillus paracasei induces M2-dominant kupffer cell polarization in a mouse model of nonalcoholic steatohepatitis[J]. Dig Dis Sci, 2015, 60(11):3340-3350.
[27]	ANEST V, HANSON JL, COGSWELL PC, et al. A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression[J]. Nature, 2003, 423(6940):659-663.
[28]	KIM YA, KEOGH JB, CLIFTON PM. Probiotics, prebiotics, synbiotics and insulin sensitivity[J]. Nutr Res Rev, 2018,31(1):35-51.
[29]	SHEN F, ZHENG RD, SUN XQ, et al. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease[J]. HBPD Int, 2017, 16(4):375-381.
[30]	IBRAHIM SH, HIRSOVA P, GORES GJ. Non-alcoholic steatohepatitis pathogenesis:sublethal hepatocyte injury as a driver of liver inflammation[J]. Gut, 2018, 67(5):963-972.
[31]	郑啼婴,李瑜元,聂玉强,等. 肠道菌群对非酒精性脂肪性肝病病变程度的影响[J]. 广州医科大学学报,2016, 1:9-13.
[32]	MALAGUARNERA M, VACANTE M, ANTIC T, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis[J]. Dig Dis Sci, 2012, 57(2):545-553.
[33]	NABAVI S, RAFRAF M, SOMI MH, et al. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease[J]. J Dairy Sci, 2014, 97(12):7386-7393.

Message Board

Role of probiotics on nonalcoholic fatty liver disease related cells

doi: 10.3969/j.issn.1006-0111.2018.05.006

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views